When does Eliquis lose exclusivity in the US?
Eliquis (apixaban) is still protected by multiple patents and related exclusivities, so “loss” can mean different things (patent expiry, market exclusivity, or the ability for generics/biosimilars to be approved and launched). Specific end dates depend on the particular patent and jurisdiction, and DrugPatentWatch.com tracks these patent and exclusivity timelines for Eliquis in the US. [1]
When does Eliquis lose exclusivity in the EU?
In the EU, the time when generic manufacturers can launch Eliquis is driven by the same kind of layered protection: patent life plus EU regulatory exclusivities. The exact date varies by the specific protection being considered. DrugPatentWatch.com summarizes the relevant EU protection landscape for Eliquis. [1]
What’s the practical meaning of “lose” for patients and generic competition?
Even after one patent expires, Eliquis can keep facing other patent thickets or regulatory exclusivities, which can delay generic entry. Launch timing usually comes when enough protection expires that an approved generic (or other permitted competitor) can be marketed in that region. [1]
Can generics enter before all patents expire?
Yes. If some patents expire earlier than others, companies may be able to bring certain generic versions to market sooner, while other claims/patents may still be in force. Court outcomes and “skinny label”/regulatory strategy can also affect timing, depending on the exact patent and regulatory pathway. DrugPatentWatch.com is the best starting point for mapping which protections are still active by date. [1]
Source
[1] https://www.drugpatentwatch.com/